NEW culturally adapted resources available now
Our Vision
Our Vision
Our vision is to reduce the devastating impact of stillbirth for women, families and the wider community through improving care to reduce the number of stillborn babies and to reduce the impact of this loss.
People + Partners
People + Partners
Meet the network of people, organisations, and professional institutions driving research and program implementation across the Stillbirth CRE.
Our work
Our Work
Explore some of the latest Stillbirth CRE research projects, scientific studies, and educational campaigns on stillbirth prevention and care after stillbirth.
Parent STories
News + Events
News + events
View the latest news and events from the Stillbirth CRE and our collaborating partners.
Get Involved
Get Involved
There's so many ways to contribute to stillbirth research. Sign up to our newsletter to stay in touch with the latest news, join our community, make a donation, or participate in research. Find out all the ways to Get Involved.
Safer Baby in pregnancy
Care after loss
Seeking Support
Research and news

Our aim is to improve care to reduce the number of stillborn babies and to reduce the impact of this loss.
Frequently asked questions
Get Involved

Stillbirth and Zika: A systematic review

Project Status Complete
Organisation Lead Columbia University
Program Area Data To Drive Change
Topic Understanding Stillbirth

Background: In 2015, there were 2.6 million stillbirths, accounting for 4.4% of all global deaths. Despite this burden, global attention to stillbirths has been limited. Evidence has accumulated that Zika virus infection causes multiple adverse outcomes, possibly including fetal demise (stillbirths, miscarriages, abortions), but there has been limited reporting and analysis of these outcomes. We aimed to summarize available data on the fetal demise burden of Zika-affected pregnancies.

Methods: This was a quasi-systematic review (PubMed, Embase, Web of Science; no language limits). Proportions of fetal demise of completed Zika-affected pregnancies were calculated. RRs for fetal demise among completed, Zika-affected versus uninfected pregnancies were estimated from cohort data.

Results: Seventeen reports included 19,928 pregnant women or infants/fetuses with confirmed, probable or suspected Zika infection. Pregnancy outcomes that included fetal demise were known for 23% (4,492). There were 244 cases of fetal demise (5%). 20% of confirmed as compared to 7% of suspected Zika-affected pregnancies ended in fetal demise. Only one cohort study included asymptomatic as well as symptomatic mothers; the crude risk of fetal demise was nearly 13 times higher for Zika-affected as unaffected mothers (RR 12.76, 95% CI 3.94, 41.37, p-value <0.0001), as compared to a crude RR of microcephaly of 6.63 (95% CI 0.78, 57.83, p-value 0.07). Most studies included only symptomatic pregnant women or infants/fetuses with Zika-related anomalies; misclassification of infection status was possible. Conclusions: Available data on fetal demise associated with Zika virus infection is limited, especially in comparison to other outcomes such as microcephaly, yet there is evidence that fetal demise may be a significant burden of Zika virus infection. Studies of Zika infection outcomes should report on fetal demise.